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Background: The World Gastroenterology Organization recommends developing national guidelines for the diagnosis
of Celiac Disease (CD): hence a profile of the diagnosis of CD in each country is required. We aim to describe a
cross-sectional picture of the clinical features and diagnostic facilities in 16 countries of the Mediterranean basin.
Since a new ESPGHAN diagnostic protocol was recently published, our secondary aim is to estimate how many
cases in the same area could be identified without a small intestinal biopsy.
Methods: By a stratified cross-sectional retrospective study design, we examined clinical, histological and laboratory
data from 749 consecutive unselected CD children diagnosed by national referral centers.
Results: The vast majority of cases were diagnosed before the age of 10 (median: 5 years), affected by diarrhea, weight
loss and food refusal, as expected. Only 59 cases (7.8%) did not suffer of major complaints. Tissue transglutaminase
(tTG) assay was available, but one-third of centers reported financial constraints in the regular purchase of the assay kits.
252 cases (33.6%) showed tTG values over 10 times the local normal limit. Endomysial antibodies and HLA typing were
routinely available in only half of the centers. CD was mainly diagnosed from small intestinal biopsy, available in
all centers. Based on these data, only 154/749 cases (20.5%) would have qualified for a diagnosis of CD without a
small intestinal biopsy, according to the new ESPGHAN protocol.
Conclusions: This cross-sectional study of CD in the Mediterranean referral centers offers a puzzling picture of
the capacities to deal with the emerging epidemic of CD in the area, giving a substantive support to the World
Gastroenterology Organization guidelines.
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Celiac disease (CD) increased at an unexpected rate in
the last two decades [1-3]. It was long considered a
problem limited to the wheat-consuming affluent societies
of the western world [4], but it was recently reported in
almost every wheat-consuming country worldwide [5]. In
the near future, most CD cases are expected to come from
Africa, Asia and South America [6-9]. We estimate that* Correspondence: ydongre@unina.it
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reproduction in any medium, provided the ormore than 5 million cases will occur in the Mediterranean
region in the next 10 years. Without a timely diagnosis and
appropriate health care, an excess mortality of more than
230,000 cases may be expected in the next decade [10].
Facilities and resources to control this modern non-
communicable disease epidemic are limited in many of
the less affluent countries of the world including some of
the Mediterranean countries. The World Gastroenterology
Organization (WGO) recognized that the ‘epidemic’ of
CD cannot be met without considering the local resources:
hence it recommended adapting the diagnostic protocol
according to available resources [11]. Recently, European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) published new diagnostic criteria
for CD to simplify CD diagnosis by avoiding small boweltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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clear symptoms, tissue transglutaminase (tTG) levels
10-fold above the upper limit of normal, positive anti-
endomysial antibodies (EMA) and specific HLA haplotype.
This new algorithm, not requiring in all cases expensive
endoscopy and pathology equipment, could facilitate
the control over the coming CD epidemic in less privi-
leged countries. The Mediterranean Network for the
Management of Food-Induced Diseases (MEDICEL), which
is an EUROMED-based action, to which all Mediterranean
countries participate (Figure 1), aims at improving aware-
ness of the forthcoming CD epidemic.
We aim to describe a cross-sectional picture of the
clinical features and diagnostic facilities in 16 countries
of the Mediterranean basin. Since the new ESPGHAN
diagnostic protocol was recently published, our secondary
aim is to estimate how many cases could be identified
without a small intestinal biopsy in the same area.
Methods
Unfortunately Syria, Lebanon and Libya did not partici-
pate to the network. Palestine was not able to comply
with the requirement for the study. Israel could not
obtain the ethical permission to use data already col-
lected for a similar study.
Each referral center from Albania, Algeria, Bosnia
Herzegovina, Croatia, Egypt, France, Greece, Italy - Messina
and Naples - Malta, Montenegro, Morocco, Slovenia, Spain,
Tunisia and Turkey provided a list of 50 unselectedFigure 1 Map of referral centers in the participating countries.consecutive CD cases diagnosed in the center by the
best locally available methodologies. Using a standardized
form, the clinical and laboratory data leading to the diag-
nosis were collected for each case. The methods used in
each center for the serum assay of tTG were recorded,
together with their local normal values. We reviewed
the pathology procedure used to evaluate small intestinal
biopsy specimens and recorded the methods used to
evaluate the HLA haplotype. EMA assay was available in
8/16 centers: due to the subjectivity of the method, we
could not obtain a standardized comparable set of results.
According to the WGO diagnostic protocol, tTG are
an acceptable proxy of the EMA antibodies, especially in
countries with limited resources (“The EMA test requires
expert observers, and ELISA tests for detecting tTG anti-
bodies should therefore be recommended in settings with
low expertise”) [11]. For these reasons, in the analysis,
we did not considered the few available EMA values.
Based on the facilities and tests available in each cen-
ter, for each case we estimated the probability of being
diagnosed with CD by the new ESPGHAN diagnostic
criteria alone, without small intestinal biopsy. For each
case we summed up the number of diagnostic criteria
met (clinical symptoms, tTG above 10 folds the upper
limit of normal and specific HLA). The sum of the cri-
teria determined the final diagnostic score, which thus
ranged from 1 to 3. To reduce large tables, countries
were often aggregated within their geographical region
(Europe, Balkans, North Africa).
Table 2 Presenting symptoms by ages
Symptoms Age (years)
0-5 6-10 11-18
Chronic diarrhea 188 (22.8%) 87 (17.9%) 55 (16.8%)
Weight loss 156 (18.9%) 78 (16%) 69 (21.1%)
Food refusal 128 (15.5%) 63 (13%) 30 (9.2%)
Vomiting 221 (26.8%) 159 (32.7%) 95 (29.1%)
Anemia 67 (8.1%) 37 (7.6%) 23 (7%)
Constipation 26 (3.2%) 18 (3.7%) 7 (2.1%)
Other symptoms 22 (2.7%) 22 (4.5%) 25 (7.6%)
No symptoms 15 (1.9%) 22 (4.5%) 23 (7%)
Total 824 (50.3%) 486 (29.7%) 327 (20%)
Table 3 Presence of the ESPGHAN diagnostic criteria in
the 749 patients
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ware package (SPSS Inc., Chicago, IL, USA). Variables
were log transformed when required because of their
not normal distribution. Student’s t test and ANOVA
were used to compare group means; non parametric
tests were used when appropriate; p values <0.05 were
considered significant.
Ethics statement
Institutional review boards at each collection site
approved the study in each country (Albania, Algeria,
Bosnia Herzegovina, Croatia, Egypt, France, Greece,
Italy, Malta, Montenegro, Morocco, Slovenia, Spain,
Tunisia and Turkey) (Additional file 1).
Results
A total of 800 forms were expected by the 16 CD refer-
ral centers of the Mediterranean Basin, 50 each, but 51
(6.3%) forms were excluded by the local centers because
of missing data, thus 749 (93.7%) CD cases were
included in the analysis.
Clinical presentation
A total of 169/749 patients (22.5%) reported a case of
CD among their first-degree relatives: mother in 44/749
(5.8%); father in 45/749 (6%); sibling in 45/749 (6%); and
more than one relative in 35/749 (4.6%) cases. The
female-to-male ratio was 1.6:1 (461 females; 288 males).
Age at diagnosis ranged from 6 months to 18 years: 388
patients (51.8%) were diagnosed within the first 5 years
of life, and 23.4% during the first two years of life. The
mean age at diagnosis was 5.97 years (SD 4.35; median
5 years). The distribution of age at diagnosis did not
differ significantly (ANOVA p >0,1) among the 3 geo-
graphical areas (Europe, Balkans and North Africa).
Since the participants are referral centers, most patients
had serious clinical complaints (Table 1). Clinical mani-
festations varied according to age (Table 2). Younger
children (1-5 years old) more often suffered fromTable 1 Frequencies of symptoms in the three macro-areas
Symptoms Area
Europe Balkans Africa
Chronic diarrhea 82 (35.3%) 149 (44.5%) 99 (54.4%)
Weight loss 81 (34.9%) 155 (46.2%) 67 (36.8%)
Food refusal 59 (25.4%) 107 (31.9%) 55 (30.2%)
Vomiting 122 (52.6%) 240 (71.6%) 113 (62.1%)
Anemia 22 (9.5%) 74 (22.1%) 31 (17.0%)
Constipation 11 (4.7%) 32 (9.5%) 8 (4.4%)
Other 13 (5.6%) 38 (11.3%) 18 (9.9%)
No symptoms 41 (17.7%) 3 (0.9%) 15 (8.3%)
Total 232 335 182diarrhea and food refusal than older children. Vomiting,
food refusal and growth impairment were common
across all ages. Older children and adolescents (>10 years)
occasionally presented with extra-intestinal manifestations
such as mood changes and anemia, but generally showed
the same symptoms as younger children.Serology tests
tTG data were available for 748 cases. The cutoff values
of normality in the various countries ranged between 7
and 20 UI/ml, and we normalized the reported raw
values for the corresponding threshold of the center.
The distribution of tTG values in times the normal local
values shows that 252 (36.6%) patients had values 10
times the normal or more and a considerable number,
103 (13.7%), of CD cases were diagnosed by a tTG level
not greater than twice the upper limit of the local nor-
mal values.Symptoms Frequency Percentage
None 59 7.9
Present 685 91.4
tTG
<10 times 496 66.2
>10 times 252 33.6
HLA
Absent 432 57.7
Present 317 42.3
ESPGHAN diagnostic criteria
1 289 38.5
2 294 39.2
3 154 20.5
Figure 2 ESPGHAN score (ESSCORE) by country.
Table 4 Correlation between tTG and Marsh stages
Country Spearman Rho p value
Albania 0.42 0.01
Algeria -0.14 0.32
Bosnia 0.09 0.58
Croatia -0.07 0.6
Egypt 0.17 0.3
France 0.06 0.6
Greece 0.007 0.9
Malta 0.18 0.9
Montenegro 0.25 0.079
Morocco 0.33 0.018
Naples 0.53 0.0001
Sicily 0.37 0.008
Slovenia 0.13 0.33
Spain -0.09 0.5
Tunisia 0.19 0.17
Turkey 0.21 0.16
Total 0.12 0.002
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706/749 (94.2%) CD patients underwent a duodenal bi-
opsy. A biopsy report was not provided for 27/43 cases
(62.8%) in Albania, for 8/42 cases (19%) in Bosnia
Herzegovina, and for 4/36 cases (11.1%) in Egypt. Mild
mucosal lesions (T0-T2) were found in 158 patients
(22.4%), while 56 (7.9%) patients had partial atrophy
(T3a), 492 (69.6%) patients had more severe atrophy
(T3b and T3c).
HLA typing
HLA typing was reported for all cases from Greece,
Naples, Slovenia and Spain, in 14/42 of cases from
Bosnia Herzegovina (33.3%), in 13/50 from Croatia
(26%), 16/50 from Messina (Sicily) (22%) and 34/50 from
Turkey (68%). HLA results were missing in countries of
North Africa (Algeria, Morocco, Tunisia and Egypt),
Albania and Montenegro. In conclusion, 368/749 CD
cases were genotyped for HLA (49.1%). Of these 285
(77.4%) carry the DQ2 heterodimer, 76 (20%) the DQ8
heterodimer, whereas 7 (1.9%) do not carry either of
these molecules.
When could the biopsy be omitted?
Table 3 shows that 91.4% of cases had clear symptoms
(criterion 1), 33.6% had x10 tTG titers (criterion 2) and
42.3% of patients underwent HLA typing (criterion 3).
When we examined the sum of criteria for each individ-
ual, we found that 39% of patients had clinical symptoms
only, 40% had two criteria, i.e., clinical symptoms plus
serum tTGx10 normal or HLA, and only 154 (20.7%) of
749 patients had all 3 criteria thereby qualifying for adiagnosis without a biopsy. HLA typing was not avail-
able for half the cases; if we assume that all these cases
had a compatible HLA, we may conclude that 304
(40.9%) cases would qualify for the biopsy-free diagnosis.
Figure 2 shows the percentage of cases with 2 and 3
criteria in the various countries. It is clear that for many
countries (Albania, Algeria, Bosnia Herzegovina, Egypt,
France, Greece, Malta and Morocco) not one case would
qualify for the biopsy-free protocol. In fact, it would be
Figure 3 Median tTG levels by Marsh grading at biopsy (Messina and Naples, Italy).
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Slovenia, Spain, Tunisia and Turkey.
Discussion
Given the worldwide increase in CD cases, there is an
impelling need to simplify the diagnostic work-up to
enable a timely diagnosis [11,12]. This is particularly true
for countries that do not have access to sophisticated
techniques. The WGO recommends evaluating the local
availability of resources to develop a diagnostic protocol.
We now provide a comprehensive picture of the diagnosis
of CD in 16 Mediterranean countries. Being in European
neighborhood area we evaluated whether the new
ESPGHAN diagnostic protocol, which could potentially
omit endoscopy and biopsy in a significant number of
cases [13,14], could be applied efficiently in the 16
countries of the Mediterranean Basin who participate
to the MEDICEL network. Indeed, in selected populations
the “triple test” criteria appear to be helpful: a Spanish
study [14] supports the view that in selected children who
are symptomatic and positive for the triple test, CD diag-
nosis could be established independently of histological
findings. Almost all cases here described were diagnosed
by a small intestinal biopsy, while the aim of the new
ESPGHAN criteria is to reduce the requirement for
such and invasive procedures. We shared among the 16
partners the importance of avoiding, at least in a per-
centage of cases, such an invasive technique.
Unfortunately, in our setting only 20% of suspected
CD cases with clear clinical symptoms might qualify for
a CD diagnosis without a small intestinal biopsy. This
percentage would have increased to about 40% if HLAtesting had been available. This limitation is not confined
to less equipped countries, but it also applies to many
European centers with a long experience in CD diagnosis.
The chance of avoiding a small intestinal biopsy is based
on the strength of the correlation between the tTG and
the stage of mucosal damage. Recently Wakim-Fleming J
et al. [15] suggested that titres of IgA tTG > 118 IU
identified patients with CD with a 2% false-positive
rate. Titres of 21-118 UI, in combination with EMA
dilution titer ≥1:160, had a positive predictive value of
83% for CD. Popp et al. [16] also found that in diabetic
patients high tTG titres predict a diagnosis of CD, when
associated to EMA positivity. The relationship between
antibodies and biopsy is crucial: we show on Table 4 the
Spearman Correlation Coefficients between the values of
the tTG(log) and the Marsh stages at biopsy in each coun-
try. It is clear that the correlation is strong and significant
only in Italy (Messina and Naples), while it is not signifi-
cant in all other countries. The basic assumption that tTG
antibodies predict severe mucosal damage is not con-
firmed in this set of data. The shape of the correlation in
Italy (Messina and Naples) shows that tTG does increase
with Marsh Stages (Spearman Rho = 0.44), but there are
very ample 95% Confidence Intervals around the median
at all Marsh stages, making the basic assumption quite
fragile also in this country (Figure 3). Based on our data,
tTG does not appear to be actually a proxy of the degree
of mucosal damage as evaluated by the Marsh score. Also
in Italy, where there is a clear correlation, the interquartile
range is very large, making this correlation unsafe to
predict the mucosal damage by the high levels of anti-
body production. Although the correlation between the
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the level of tTG antibodies has been confirmed in sev-
eral relevant studies [13], this correlation has several
weakness, due to the nature of the data. tTG antibodies,
as all antibodies, do not have a normal distribution, but
a logarithm distribution and Marsh stages have an
ordinal distribution, not a continuous one. So the rela-
tionship between these two variables is intrinsically
prone to large or very large confidence intervals, which
reflect not only the nature of the variables, but also the
wide polymorphism of the phenotype of the disease. The
quality of serological test and the scarcity of HLA testing
are the critical points that, at present, limit the chance to
diagnose CD without a biopsy.
Unfortunately, in several of the participating referral
centers, the laboratory experience to assay the tTG is
limited and performed only when financial resources are
available. Some laboratories produce semi-quantitative
data, increasing the uncertainty of the assessment. One
of the objectives of the MEDICEL network is to support
the upgrading of local diagnostic resources: hence we are
now running ad hoc procedure to standardize the method
of antibody assay and to increase the availability of HLA
haplotyping by exploiting the new technologies that
attempt to bring the test to the point of care [17,18].
This cross-sectional study provides the first picture of
the profile of CD in the countries studied and of the
diagnostic resources available in the referral centers.
Most cases were symptomatic showing the classical clin-
ical profile. This will probably change significantly in the
near future when awareness about CD increases, as has
occurred in several European countries [3,10]. This study
suffers from the objective limitation of being a retrospect-
ive study. Nevertheless, we needed a cross-sectional pic-
ture of the pattern of celiac disease in the area, for
which this kind of study is rapidly informative. In the
same area we have already started a prospective study in
order to validate the findings of this actual study.
Conclusion
In conclusion, this cross-sectional survey provides a multi-
faceted picture of the CD domain in the Mediterranean
area. Being aware of the expanding epidemic of CD over
the wheat consuming populations, we hope that simplified
diagnostic criteria, possibly avoiding the expensive biopsy,
could help to diagnose cases outside the very few referral
centers in developing countries. Unfortunately this study
does not support this chance to date, but does iden-
tify the critical points to be met in order to expand the
advantages of the new ESPGHAN diagnostic protocol,
especially in countries that need this change the most.
These results provide to each participant country re-
quired data to develop local strategies according to the
WGO recommendations.Additional file
Additional file 1: National Ethical Permissions.
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